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Approximately 5–10% of breast cancer patients have some degree
of family history and may be carriers of an inherited susceptibility
to the disease (Claus et al, 1996). However, mutations in the two
major breast cancer susceptibility genes, BRCA1 and  BRCA2
(Miki et al, 1994; Wooster et al, 1995), have been found only in
about 20% of Finnish high-risk breast cancer families (Vehmanen
et al, 1997a, b; Huusko et al, 1998). Very recently, the chromo-
somal location of a new susceptibility gene was identified (Kainu
et al, 2000). This and other genes, such as TP53,  PTEN, and
possibly ATM, are responsible for an additional fraction of breast
cancer predisposition (reviewed in Easton, 1999). 
Somatic mutations in the TP53 gene are found in almost all kinds
of tumours (Hollstein et al, 1991). Mutations are usually clustered
within the most conserved regions of exons 4, 5, 7 and 8, corre-
sponding to the sequence-specific DNA binding domain of the
protein (Levine, 1997). Germline TP53 mutations have been found
in patients with the rare Li-Fraumeni syndrome (LFS), characterized
by breast cancer, osteosarcoma, leukaemia, brain and adrenocortical
tumours at an early age (Birch et al, 1994; Varley et al, 1997b;
reviewed in Eng et al, 1997 and Varley et al, 1997a). A similar
cancer phenotype has recently been observed in patients carrying
hereditary mutations in the checkpoint kinase gene, CHK2, indi-
cating genetic heterogeneity within LFS (Bell et al, 1999). 
In the previous study by Huusko et al (1999), we screened 7
Finnish LFS and Li-Fraumeni-like (LFL) families for TP53 exon
5–8 mutations. Two changes were identified (Tyr220Cys and
Asn235Ser), both of which appeared to associate with accumula-
tion of female breast cancer. Based on these results, we wanted to
see whether germline TP53 mutations could also explain familial
breast cancer cases without LFS/LFL phenotype and if mutations
could be found outside the conserved segment. We also anticipated
finding geographical clustering, because of the strong founder
effects regarding BRCA1 and  BRCA2 mutations in Finland
(Huusko et al, 1998; Sarantaus et al, 2000). Here, a large cohort of
130 breast cancer patients from 108 Finnish BRCA1 and BRCA2
mutation-negative breast cancer families were screened for TP53
germline alterations covering the entire protein encoding region
(exons 2–11) of the gene. 
We analysed 130 subjects from 108 Finnish BRCA1 and BRCA2
mutation-negative breast cancer families (Vehmanen et al, 1997a,
b; Huusko et al, 1998). Of these families, 5 had previously been
studied for TP53 exon 5–8 mutations (Huusko et al, 1999).
Geographically, the families originated from 3 regions of Finland:
79 from the Oulu University Hospital area, 13 from the Tampere
University Hospital area and 16 from the Helsinki University
Central Hospital area. The criteria for inclusion were 3 or more
cases of breast cancer in first- or second-degree relatives, early
disease onset (≤ 35 years), bilateral breast cancer, or multiple
tumours including breast cancer in the same individual. 75 fam-
ilies met the criteria for moderate- to high-risk hereditary breast
cancer only, 32 for both hereditary breast cancer and LFL, and 1
for both hereditary breast cancer and LFS (Table 1; Birch et al,
1994; Eng et al, 1997). To search for founder effects, additional
BRCA1 and BRCA2 mutation-negative breast cancer families (50
for Tyr220Cys and Asn235Ser, and 5 for Arg248Gln), originating
from the same geographical regions as those with the identified
mutations, were analysed. In addition, DNAs from 500 unselected
consecutive breast cancer patients from the Tampere region were
used to establish the mutation frequency in the population.
Informed consent to obtain pedigree data and a blood specimen for
the study was obtained from all patients. The Ethical Boards of the
participating hospitals and the Finnish Ministry of Social Affairs
and Health have approved the study. 
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Using genomic DNA, TP53 exons 2–11 were screened by
conformation sensitive gel electrophoresis (CSGE) or fluo-
rescense-CSGE as described earlier (Ganguly et al, 1998; Huusko
et al, 1998). Samples with a band shift were sequenced as
instructed by the apparatus manufacturer Li-Cor (Lincoln, USA).
DNAs from 500 unselected consecutive breast cancer cases 
were screened using DNA minisequencing (Syvänen, 1999).
Oligonucleotide sequences were designed based on GenBank
sequence information (U94788). 
In the present study, 108 breast cancer families were screened
for TP53 mutations. This is a considerably larger number of fam-
ilies fulfilling the criteria of hereditary breast cancer than in any
previous study. The CSGE and F-CSGE analyses of exons 2–11
revealed a constitutional TP53 alteration, Arg248Gln, in one of the
studied families. In addition, one silent variant (Arg213Arg) and
other known polymorphisms in the intronic region between the
exons 2 and 3, as well as in exon 4, were detected (data not shown). 
The subject with the Arg248Gln (CGG→ CAG) mutation 
showed strong family history of breast cancer. The cancer
spectrum of this family (#6001, Figure 1A) also matches the LFL
criteria (Birch et al, 1994; Eng et al, 1997). Immunohistochemical
analysis results from patient records revealed positive p53 staining
in the tumours of all three of the mutation carriers. 
Arg248 resides in the highly conserved region of exon 7 and is
the most frequently altered residue of the p53 protein, being essen-
tial for DNA binding functions (Cho et al, 1994). Therefore, the
Arg248Gln substitution leads to defective contacts with target
DNA. Agr248Gln has most frequently been detected in colorectal
and breast tumours (Lasky and Silbergeld, 1996). It is also the
most commonly found alteration in LFS (Shibata et al, 1996). In
the family carrying Arg248Gln (Figure 1A), we were unable to
determine the mutational status of the proband’s (case 19) paternal
grandparents. Since they both died at an old age without evidence
of cancer, it is possible that this is a de novo mutation. 
Screening of the Arg248Gln mutation and the previously
detected two Finnish germline TP53 mutations (Tyr220Cys,
Asn235Ser; Huusko et al, 1999) was expanded to include 500
unselected consecutive breast cancer cases. No mutations were
found, suggesting that the frequency of these mutations is very low
in the general breast cancer population. Our results support the
observation that TP53 alterations are rare and explain only a negli-
gible fraction of breast cancer cases at the population level, mainly
associated with strong family history of breast cancer. There was
no evidence of founder effects that otherwise are common in
hereditary diseases in Finland. This may be due to the
rareness/young age/more severe effect on survival of the studied
TP53 mutations, as compared to the situation in for instance
HNPCC- (Nyström-Lahti et al, 1995) and BRCA1/BRCA2-related
cancer predisposition (Huusko et al, 1998; Sarantaus et al, 2000).
Evidence against founder effects was also obtained by studying
additional breast cancer cases originating from the same geograph-
ical areas as those with mutations. 
Taking together the two studies, we have analysed the entire
TP53 protein-encoding region in 108 breast cancer families and
found mutations in three (2.8%) of them (Figure 1). This
frequency is in agreement with the concept that mutations prefer-
entially occur in LFS/LFL-related patients. Zeleda-Hedman et al
(1997), Warren et al (1992), Prosser et al (1991) and Patel et al
(1995) studied 109, 25, 5 and 4 breast cancer families, respect-
ively, without finding any mutations. Boerresen et al (1992)
studied 237 women with breast cancer, of which 30 had at least
one first-degree relative with breast cancer, 40 had breast cancer
before age 35, and 167 represented unselected breast cancer
patients. Only one unselected and one early-onset patient were
found to carry a mutation. On more detailed review, both of these
cases had a family history of breast cancer and other malignancies
suggestive of LFS. Lidereau and Soussi (1992) studied 19 unre-
lated cases with bilateral breast cancer, but no TP53 mutations
were detected. Breast and other cancers had occurred in the relat-
ives of 7 of the 12. Sidransky et al (1992) found 1 of 126 patients
with early-onset breast cancer carrying a germline change. These
earlier mutation analyses have usually been limited to exons 5–8.
Due to recent observations that the mutations could also reside in
domains responsible for transcription and oligomerization control
(exons 2–4 and 9–11) (Varley et al, 1997a), we decided to investi-
gate these regions too. However, our results support the existing
view (Toguchida et al, 1992; Birch et al, 1994; Cornelis et al,
1997; Varley et al, 1997b), suggesting that the breast cancer
Table 1 Summary classification of all studied 108 cancer families according
to occurrence of breast, other LFS/LFL-associated (osteosarcoma,
leukaemia, brain or adenocortical tumours) and other cancers in 1st and 2nd
degree relatives 
No. of breast  No. of other No. of LFS/LFL-
cancer cases  cancers within associated cancers
within a family a family within a family 
01 2 3 4 5 6





2 69 9 1 1 0 




3 55 1 0 12 1 3 0 




4 11 3 1 1 0 














Total no. of families: 108 
Numbers in bold indicate the total number of families in each class. Of the
130 breast cancer cases, 12 (9%) were identified at or below age 35, 86
(66%) between ages 36–60, and 32 (25%) at or above age 61.predisposing TP53 mutations mainly occur at specific mutation-
prone regions (exons 6–7) of the conserved parts of the gene. 
All 3 Finnish TP53 germline mutations affect mutation-prone
sites and have been observed previously: Tyr220Cys and
Arg248Gln in LFS/LFL families (Birch et al, 1994; Varley et al,
1997b), and Asn235Ser in LFS-associated malignancies, but with
an uncertain familial background of cancer predisposition
(Wagner et al, 1994; Diller et al, 1995; Cornelis et al, 1997).
Available data may therefore suggest that Asn235Ser could be
associated with variable cancer susceptibility and reduced pene-
trance. Results from both our (Figure 1) and other studies indicate
that these mutations may be associated in particular with female
breast cancer, frequently bilateral, and young age of onset, in
combination with other signatures of LFS or LFL. 
In conclusion, this systematic, large-scale study of germline TP53
alterations among breast cancer families indicates that mutations in
the conserved regions of the gene seem to explain only a very small
fraction of the Finnish BRCA1 and BRCA2 mutation-negative breast
cancer cases, and that additional and more important hereditary
breast cancer susceptibility genes remain to be identified. 
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